Stockreport

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

Xilio Therapeutics, Inc.  (XLO) 
PDF XTX202, a tumor-activated IL-2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T ce [Read more]